SILVER SPRING, Md. - An FDA panel Wednesday in a 16-to-1 vote, with one abstention, rejected NicOx SA's naproxcinod, a cyclooxygenase-inhibiting nitric oxide-donating compound, as a treatment to relieve the signs and symptoms of osteoarthritis. (BioWorld Today) Read More